Immunosuppressive therapy of chronic idiopathic thrombocytopenic purpura |
| |
Authors: | S C Finch O Castro M Cooper W Covey R Erichson P McPhedran |
| |
Affiliation: | New Haven, Connecticut USA;Bridgeport, Connecticut USA;Stamford, Connecticut USA;New Haven, Connecticut USA |
| |
Abstract: | The results of 17 courses of immunosuppressive therapy in 12 adult patients with chronic idiopathic thrombocytopenic purpura were compared to those reported in 94 patients in the literature. About 50 per cent of the reported patients with chronic idiopathic thrombocytopenic purpura treated with immunosuppressive drugs have had a successful response. In most of these, however, the idiopathic thrombocytopenic purpura was of short duration which suggests that many of the responses were spontaneous. The probability of response to immunosuppressive agents is much greater in the splenectomized patient than in the nonsplenectomized patient.Azathioprine and cyclophosphamide are the drugs of choice for the immunosuppressive therapy of chronic idiopathic thrombocytopenic purpura. The immunosuppressive effects of cyclophosphamide probably are better, but the potential complications of this drug in patients with chronic idiopathic thrombocytopenic purpura are more serious. Nonsteroidal immunosuppressive therapy should be used as the primary form of treatment only in patients with serious disease who fail to respond to corticosteroid therapy and who are poor risks for splenectomy. One or more courses of nonsteroidal immunosuppressive therapy may be indicated in patients with chronic refractory idiopathic thrombocytopenic purpura with life-threatening disease. It is expected that from 15 to 35 per cent of adults and probably more children with chronic refractory idiopathic thrombocytopenic purpura will have a successful response.The use of nonsteroidal immunosuppressive drugs in patients with chronic idiopathic thrombocytopenic purpura remains experimental and involves uncertain risks to the patient. |
| |
Keywords: | Requests for reprints should be addressed to Dr. Stuart C. Finch Department of Internal Medicine Yale University School of Medicine 333 Cedar Street New Haven Connecticut 06510. |
本文献已被 ScienceDirect 等数据库收录! |